On the basis of these, METTL13 has a great potential to act as a new diagnostic biomarker and therapeutic target for ccRCC in the future, while its molecular mechanisms are worthy of further validation and investigation. This evidence concerns the gene METTL13 and nonpapillary renal cell carcinoma.